Welcome to our dedicated page for Tenax Therapeutics SEC filings (Ticker: TENX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tenax Therapeutics filings document a Phase 3, development-stage pharmaceutical company developing cardiopulmonary therapies, including TNX-103 (oral levosimendan) for PH-HFpEF. Recent 8-K reports record financial results, clinical program updates for LEVEL and LEVEL-2, intellectual-property notices, and amendments to levosimendan license rights, including expanded worldwide rights for orally administered products.
Proxy and current-report filings also describe Nasdaq-listed common stock, executive appointments, employment and compensation arrangements, equity awards, governance matters, and named-executive pay disclosures. These records frame the company's capital structure, leadership responsibilities, material agreements, and clinical-stage operations around levosimendan development and commercialization rights.
T. Rowe Price Associates files an amended Schedule 13G reporting beneficial ownership of 586,990 shares of Tenax Therapeutics common stock. The filing states this represents 2.2% of the class and lists sole voting and sole dispositive power over those shares. The cover shows 05/31/2026 and the amendment is signed on 06/05/2026.
The filing is marked under the heading "Ownership of 5 Percent or Less of a Class," and includes a statement denying that the filer is the beneficial owner. No transaction price, acquisition date, or purchase method is disclosed in the excerpt.
Tenax Therapeutics, Inc. reported the results of its 2026 annual meeting of stockholders held on June 2, 2026. Stockholders elected seven directors, including June Almenoff, Michael Davidson, Declan Doogan, Christopher T. Giordano, Robyn M. Hunter, Gerald T. Proehl, and Stuart Rich, each to serve a one-year term expiring in 2027.
Each director nominee received between 15,762,162 and 17,397,413 votes in favor, with additional withheld votes and 3,742,678 broker non-votes recorded for each. Stockholders also ratified the appointment of Cherry Bekaert LLP as the company’s independent registered public accounting firm for the year ending December 31, 2026, with 21,304,543 votes for, 3,688 against, and 11,073 abstentions.
Tenax Therapeutics Schedule 13G shows Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander report shared voting and dispositive power over 1,347,130 shares of Tenax common stock, representing 5.1% of the class as of 05/18/2026.
The filing states these shares are held by entities subject to voting control and investment discretion by Millennium Management LLC and related managers. The filing is a joint statement and is signed by the reporting parties on 05/19/2026.
Tenax Therapeutics, Inc. reports that Logos Global Management and related reporting persons jointly disclose beneficial ownership of 800,000 shares of Common Stock, representing 3.0% of the class based on 26,525,159 shares outstanding as of May 8, 2026. The filing states shared voting and dispositive power for the 800,000 shares and is signed by William Arsani on behalf of the reporting persons on 05/15/2026.
Tenax Therapeutics reported a Schedule 13G/A showing Stonepine entities and Jon M. Plexico jointly hold 975,200 shares of Common Stock, representing 3.7% of the class. The filing states the percentage is calculated based on 26,525,159 shares outstanding as of May 8, 2026.
The reporting persons disclose shared voting and dispositive power over the 975,200 shares and disclaim sole voting or dispositive power. The statement is signed by Jon M. Plexico on behalf of the reporting persons.
Tenax Therapeutics ownership update: a group of related Venrock entities and two individuals report aggregate beneficial ownership equal to 9.99% of Tenax Therapeutics common stock as of March 31, 2026, reflecting a contractual "Beneficial Ownership Blocker." The group reports shared beneficial ownership of 1,955,105 shares, and the filing cites 17,197,613 shares outstanding as of March 6, 2026 as the base for the percentage calculation. The filing lists component holdings, including 1,382,092 shares held by Venrock Healthcare Capital Partners EG, L.P., and describes warrants and pre-funded warrants subject to the blocker that limit further exercises above the stated ownership cap.
Tenax Therapeutics filing amended Schedule 13G/A reporting that Point72-affiliated persons beneficially own 533,965 shares of common stock, representing 3.1% of the class as of the close of business on March 31, 2026. The holdings are reported for Point72 Asset Management, Point72 Capital Advisors Inc., and Steven A. Cohen.
The filing states the shares are held by an investment fund managed by Point72 Asset Management; the reporting persons assert shared voting and dispositive power over the 533,965 shares. Signature block shows authorization by Jason M. Colombo dated 05/15/2026.
TENAX THERAPEUTICS, INC. amendment reports that Lind Global Fund II LP, Lind Global Partners II LLC and Jeff Easton each disclose ownership tied to 202,480 warrants to purchase common stock. The filing states those Warrants represent 0.78% of the class and contain a 9.9% beneficial ownership cap.
The Reporting Persons list a principal business address of 444 Madison Ave, Floor 41, New York, NY 10022 and the issuer address as 101 Glen Lennox Drive, Suite 300, Chapel Hill, NC 27517. Signatures are dated 05/15/2026.
TENAX THERAPEUTICS, INC. ownership update: a group of related investment entities led by Biotechnology Value Fund and affiliated entities reported aggregate derivative and equity holdings and the limits that constrain exercise rights. As of March 31, 2026, the Reporting Persons held Pre-Funded Warrants exercisable for an aggregate of 9,407,095 shares and Warrants for 4,851,812 shares; exercise blockers limit immediate conversion to 1,569,173 shares for the Reporting Persons. Based on the filing’s denominator (including outstanding shares and certain issuable shares), individual reported beneficial ownership percentages range from 0% to approximately 9.99% for affiliated entities and individuals.
Perceptive Advisors, Joseph Edelman and Perceptive Life Sciences Master Fund report beneficial ownership of 1,447,782 shares of Tenax Therapeutics common stock. The holdings represent 5.5% of the class based on 26,525,159 shares outstanding as of May 8, 2026, per the issuer's Form 10-Q filed May 12, 2026.
The Master Fund directly holds the shares; Perceptive Advisors serves as the Master Fund's investment manager and Mr. Edelman is the managing member of Perceptive Advisors, each of whom may be deemed to beneficially own the same block. Shared voting and dispositive power are reported for the full block.